Atherosclerosis and its manifestations namely
cardiovascular diseases (CVD) are still the leading cause of morbidity and mortality worldwide. Although intensified interventions have been applied, the residual cardiovascular (CV) risks are still very high.
Lipoprotein-associated phospholipase A2 (Lp-PLA(2)) is a novel and unique
biomarker highly specific for vascular
inflammation and
atherosclerosis. Both pro-atherogenic property of
Lp-PLA(2) and positive correlation with CV events have already been demonstrated by a large number of scientific and clinical studies. Currently, in the Adult Treatment Panel III (
ATP III) guideline,
Lp-PLA(2) has been recommended as an adjunct to traditional risk factors in assessing future CV risks. Encouragingly,
darapladib, an orally
Lp-PLA(2) specific inhibitor, has been tested in basic research and preclinical trials and the outcomes are quite striking. Additionally, there are two phase III ongoing clinical trials in evaluating the efficacy and safety of
darapladib on cardiovascular outcomes. With regard to the potential values of
Lp-PLA(2) in risk stratification, therapeutic regimen establishment and prognosis evaluation in patients with moderate or high risk, our present review is going to summarize the relevant data about the bio-chemical characteristics of
Lp-PLA(2), the actions of
Lp-PLA(2) on
atherosclerosis and the results of
Lp-PLA(2) in scientific research and clinical studies.